CARSGEN-B (02171) rose more than 9% against the broader market trend. As of press time, the stock was up 7.08% at HK$10.74, with turnover of HK$19.8707 million.
On the news front, on November 14, the 2026 Commercial Health Insurance Innovative Drug List was announced. CARSGEN's Kailimei® (sureucabtagene autoleucel injection) was included in the Commercial Insurance Innovative Drug List, becoming the first solid tumor CAR-T cell therapy product to be included since the establishment of the list.
Public information shows that Kailimei® is the world's first-in-class autologous CAR-T cell therapy product targeting the Claudin18.2 protein, and also the world's first approved and marketed solid tumor CAR-T cell therapy product. The drug was approved for marketing by the National Medical Products Administration in June 2026 for the treatment of Claudin18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) that has failed at least second-line therapy.
Comments